Drug Profile
Muraglitazar
Alternative Names: BMS-298585; PargluvaLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Amino acids; Antihyperglycaemics; Oxazoles
- Mechanism of Action Peroxisome proliferator-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Lipid metabolism disorders; Type 2 diabetes mellitus
Most Recent Events
- 18 May 2006 Discontinued - Clinical-Phase-Unknown for Lipid metabolism disorders in USA (PO)
- 18 May 2006 Discontinued - Phase-II for Type-2 diabetes mellitus in Japan (unspecified route)
- 18 May 2006 Discontinued - Preregistration for Type-2 diabetes mellitus in USA (unspecified route)